Quidel Stock Price, News & Analysis

Quidel Corporation (NASDAQ: QDEL) will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 1:30 p.m. Eastern time. Douglas Bryant, the CEO, will discuss the company's business and financial developments, followed by a Q&A session. A live webcast of the presentation will be available on Quidel's Investor Relations website, along with an audio archive for 14 days post-event. Quidel is a leader in rapid diagnostic testing solutions and aims to enhance global healthcare quality.

Quidel Corporation (NASDAQ: QDEL) reports its antigen tests, including QuickVue and Sofia, effectively detect the Omicron variant of COVID-19. CEO Douglas Bryant noted ongoing evaluations using live samples confirm prior findings from FDA RADx studies. Quidel is increasing production of its antigen tests to enhance community access. The company remains committed to monitoring COVID-19 variants to assure product efficacy. With over 40 years in diagnostics, Quidel continues to lead in rapid testing solutions.

Quidel Corporation (NASDAQ: QDEL) has announced a definitive agreement to acquire Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX) for $24.68 per share, totaling approximately $6 billion. This acquisition, representing a 25% premium over Ortho's prior closing price, aims to enhance Quidel's diagnostic capabilities across over 130 countries. The transaction is expected to yield annual cost synergies of $90 million and revenue synergies exceeding $100 million by 2025, enhancing Quidel's product innovation and operational efficiency.

Quidel Corporation (NASDAQ: QDEL) has secured a multi-year partnership with the Chicago Blackhawks to promote community health initiatives. This partnership features the donation of QuickVue At-Home OTC COVID-19 Tests to community partners, aiming to enhance healthcare access for local youth. The QuickVue test yields results in 10 minutes, demonstrating a proven accuracy of 83.5% for positive results and 99.2% for negative results. Additionally, the partnership includes marketing opportunities during games, reflecting Quidel's commitment to equitable healthcare.

Quidel has launched a series of infographics to educate Americans about Lyme disease, which affects nearly 480,000 individuals annually. The resources detail characteristics, warning signs, and areas of prevalence, emphasizing the importance of awareness for outdoor enthusiasts. Quidel's Sofia® 2 Lyme FIA test offers results within 15 minutes, a significant improvement over traditional testing methods. The infographics and additional educational content are available at LymeDiseaseAnswers.com.

Quidel Corporation (NASDAQ: QDEL) announced its ongoing commitment to monitor and detect COVID-19 variants, particularly the Omicron variant. CEO Douglas Bryant stated that their PCR assays can cover all known sequences of Omicron, ensuring detection through in silico analysis. The company is also ramping up its manufacturing capacity to produce 70 million tests monthly by year-end. These efforts aim to provide affordable testing solutions to communities.

Quidel Corporation (NASDAQ: QDEL) participated in the 33rd Annual Piper Sandler Healthcare Conference, discussing its business and financial developments. The virtual fireside chat's recording is accessible for 90 days via Quidel's website. With over 40 years in the medical device industry, Quidel has pioneered rapid diagnostic testing solutions for various diseases, including COVID-19. The company focuses on providing accurate and affordable testing globally, under trusted brands like Sofia® and QuickVue®.

Quidel Corporation (NASDAQ: QDEL) reported strong financial results for Q3 2021, with total revenues of $509.7 million, a 7% increase from Q3 2020. Sales of COVID-19 products rose to $402.6 million, while influenza product sales grew to $13.8 million. GAAP EPS was $5.08, down from $5.33 in 2020. The company resolved litigation with Beckman Coulter, expecting annual cash payments between $70 million and $75 million. Quidel secured a $500 million agreement with the U.S. government for COVID-19 tests, and received CE Mark for its Savanna platform.

Quidel Corporation (QDEL) has announced its sponsorship of the Distinguished Speaker Series by the Bay Area Lyme Foundation, aimed at enhancing public awareness and education about Lyme disease. The series features expert speakers discussing important topics related to Lyme disease. Quidel's Sofia® 2 Lyme FIA test offers rapid diagnostic results, providing vital information within 15 minutes. This initiative supports the rising number of Lyme disease cases expected to reach 476,000 in the U.S. by year-end, promoting easier diagnosis and treatment.